EVX-APC-RBD

**EVX-APC-RBD** is an experimental **DNA vaccine** developed by **Evaxion Biotech** as part of its SARS-CoV-2 vaccine research program. It uses Evaxion's antigen-presenting-cell targeting plasmid vaccine approach and encodes the **receptor-binding domain** of the SARS-CoV-2 spike protein, with the goal of inducing both **neutralizing antibody responses** and **T-cell immunity** against COVID-19. Publicly available information indicates the candidate was reported in **preclinical proof-of-concept** studies in mice, where it generated RBD-directed immune responses comparable to levels seen in convalescent human sera; there is no clear evidence from the identified sources that it advanced into registered human clinical development.